• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Ligand Pharmaceuticals Incorporated

    7/22/26 4:52:54 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGND alert in real time by email
    S-8 1 d140387ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on July 22, 2026

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Ligand Pharmaceuticals Incorporated

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   77-0160744

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    555 Heritage Drive, Suite 200

    Jupiter, Florida

      33458
    (Address of principal executive offices)   (Zip Code)

    Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan, as amended and restated

    (Full title of the plan)

    Todd C. Davis

    Chief Executive Officer

    Ligand Pharmaceuticals Incorporated

    555 Heritage Drive, Suite 200

    Jupiter, Florida 33458

    (Name and address of agent for service)

    (858) 550-7500

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Sean M. Donahue, Esq.

    Paul Hastings LLP

    2050 M Street NW

    Washington, DC 20036

    (202) 551-1700

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large Accelerated Filer   ☒    Accelerated Filer   ☐
    Non-Accelerated Filer   ☐    Smaller Reporting Company   ☐
         Emerging Growth Company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 600,000 shares of common stock of Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”) available for issuance under the 2002 Plan (as defined below). On June 5, 2026, our stockholders adopted an amendment and restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan, as amended and restated effective June 14, 2024 (such amended and restated plan effective June 5, 2026, the “2002 Plan”) that, among other things, increased the number of shares available for grant and issuance under the 2002 Plan by 600,000 shares. We previously filed a Registration Statement on Form S-1 (File No. 333-131029) with the Securities and Exchange Commission (the “Commission”), to register shares of common stock available for issuance under the 2002 Plan at a time when Ligand was not eligible to file a Registration Statement on Form S-8. However, Ligand later became eligible to file a Registration Statement on Form S-8 and opted to file a Post-Effective Amendment No. 2 on Form S-8 to the Registration Statement on Form S-1 for the purpose of converting the Registration Statement on Form S-1 into a Registration Statement on Form S-8. Please see the Registration Statement on Form S-1 filed with the Commission on January 13, 2006, Amendment No. 1 to Form S-1 Registration Statement filed with the Commission on February 10, 2006, and Post-Effective Amendment No. 2 on Form S-8 to Form S-1 Registration Statement filed with the Commission on June 18, 2007 for further detail. In accordance with Instruction E to Form S-8, the contents of these prior registration statements and the registration statements on Form S-8, File No. 333-182547, File No. 333-160132, File No. 333-117129, File No. 333-106375, File No. 333-91414, File No. 333-212775, File No. 333-233130, File No. 333-252480, File No. 333-265545, File No. 333-277587, and File No. 333-280733 previously filed with respect to the 2002 Plan, are hereby incorporated by reference.


    PART I

    The documents containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). These documents and the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    PART II

     

    Item 3.

    Incorporation of Documents by Reference.

    The Commission allows us to incorporate by reference the information we file with it, which means that we can disclose important information to you by referring to those documents. The information incorporated by reference is an important part of this Registration Statement, and information that we file later with the Commission will automatically update and supersede this information. We incorporate by reference the following documents we have filed, or may file, with the Commission:

    (1) the description of our common stock contained in our Registration Statement on Form 8-A filed with the Commission on November 21, 1994, and any amendment or report filed for the purpose of updating such description;

    (2) our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Commission on February 27, 2026;

    (3) the information specifically incorporated by reference into our Annual Report on Form 10-K for the fiscal year ended December  31, 2025 from our Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 21, 2026;

    (4) our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 filed with the Commission on May 8, 2026;

    (5) our Current Reports on Form 8-K filed with the Commission on April  27, 2026, April  30, 2026, May  18, 2026, June  9, 2026, June  22, 2026, June  25, 2026 and July 14, 2026; and

    (6) all documents filed by us with the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), after the date of this Registration Statement and prior to the termination of this offering of securities.

    Any statement incorporated herein shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. Under no circumstances will any information filed under current item 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to current item 9.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

     

    Item 4.

    Description of Securities.

    Not applicable.

     

    Item 5.

    Interests of Named Experts and Counsel.

    Not applicable.


    Item 6.

    Indemnification of Directors and Officers.

    Subsection (a) of Section 145 of the General Corporation Law of the State of Delaware (referred to as the “DGCL”) empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful.

    Subsection (b) of Section 145 empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in any of the capacities set forth above, against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

    Section 145 further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a) and (b) of Section 145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section 145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section 145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person’s heirs, executors and administrators. Section 145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section 145.

    Section 102(b)(7) of the DGCL provides that a corporation’s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL or (iv) for any transaction from which the director derived an improper personal benefit.

    Our amended and restated certificate of incorporation provides for indemnification of its directors, officers, employees and other agents to the maximum extent permitted by the DGCL, and our bylaws provide for indemnification of its directors, officers, employees and other agents to the maximum extent permitted by the DGCL.

    In addition, we have entered into separate indemnification agreements with our directors and officers which may be broader than the specific indemnification provisions contained in the DGCL. These indemnification agreements may require us, among other things, to indemnify our officers and directors against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also may require us to advance any expenses incurred by the directors or officers as a


    result of any proceeding against them as to which they could be indemnified. In addition, we have purchased a policy of directors’ and officers’ liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment in some circumstances. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.

     

    Item 7.

    Exemption from Registration Claimed.

    Not applicable.

     

    Item 8.

    Exhibits.


    Exhibit
    Number
       Exhibit Description    Incorporated by Reference      Filed
    Herewith
     
       Form      File No.      Exhibit      Filing Date  
    3.1    Amended and Restated Certificate of Incorporation of the Company      S-4        333-58823        3.1        07/09/1998     
    3.2    Fifth Amended and Restated Bylaws of the Company      8-K        001-33093        3.1        4/19/2024     
    3.3    Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company dated June 14, 2000      10-K        000-20720        3.5        03/29/2001     
    3.4    Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company dated June 30, 2004      10-Q        000-20720        3.6        08/05/2004     
    3.5    Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated November 17, 2010      8-K        001-33093        3.1        11/19/2010     
    3.6    Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated June 19, 2018      S-8        333-233130        3.6        08/08/2019     
    4.1    Specimen stock certificate for shares of the common stock of the Company      10-K        001-33093        4.1        03/01/2018     
    4.2    Description of Registered Securities      10-K        001-33093        4.3        02/24/2021     
    4.3    Indenture, dated as of August  14, 2025, by and between Ligand Pharmaceuticals Incorporated and U.S. Bank National Association, as Trustee.      8-K        001-33093        4.1       
    August 14,
    2025
     
     
      
    4.4    Form of Global Note, representing Ligand Pharmaceuticals Incorporated’s 0.75% Convertible Senior Notes due 2030 (included as Exhibit A to the Indenture filed as Exhibit 4.1).      8-K        001-33093        4.2       
    August 14,
    2025
     
     
      
    4.5    Indenture, dated as of June  25, 2026, by and between Ligand Pharmaceuticals Incorporated and U.S. Bank National Association, as Trustee.      8-K        001-33093        4.1       
    June 25,
    2026
     
     
      
    4.6    Form of Global Note, representing Ligand Pharmaceuticals Incorporated’s 0.00% Convertible Senior Notes due 2031 (included as Exhibit A to the Indenture filed as Exhibit 4.1).      8-K        001-33093        4.2       
    June 25,
    2026
     
     
      
    5.1    Opinion of Paul Hastings LLP                  X  
    10.1    2002 Stock Incentive Plan, as amended and restated effective June 5, 2026     
    DEF
    14A
     
     
         001- 33093       
    Appendix
    B
     
     
        
    June 5,
    2026
     
     
      
    23.1    Consent of Ernst & Young LLP, independent registered public accounting firm                  X  
    23.2    Consent of Paul Hastings LLP (included in Exhibit 5.1 hereto)                  X  
    24.1    Power of Attorney (see signature page)                  X  
    107    Calculation of Filing Fee Table                  X  

     

    Item 9.

    Undertakings.

     

    (a)

    The undersigned Registrant hereby undertakes:

     

    (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:


    (i)

    To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Table” in the effective registration statement; and

     

    (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if this registration statement is on Form S-8 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)

    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Jupiter, State of Florida, on July 22, 2026.

     

    Ligand Pharmaceuticals Incorporated
    By  

    /s/ Todd C. Davis

     

    Todd C. Davis

    Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Todd C. Davis and Octavio Espinoza, and each of them acting individually, as his or her attorney-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or any substitute, may do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:


    Signature

      

    Title

     

    Date

    /s/ Todd C. Davis

    Todd C. Davis

      

    Chief Executive Officer and

    Director (Principal Executive Officer)

      July 22, 2026

    /s/ Octavio Espinoza

    Octavio Espinoza

      

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

      July 22, 2026

    /s/ John W. Kozarich

    John W. Kozarich, Ph.D.

       Chairman   July 22, 2026

    /s/ Jason M. Aryeh

    Jason M. Aryeh

       Director   July 22, 2026

    /s/ Nancy R. Gray

    Nancy R. Gray, Ph.D.

       Director   July 22, 2026

    /s/ Jason Haas

    Jason Hass

       Director   July 22, 2026

    /s/ John L. LaMattina

    John L. LaMattina, Ph.D.

       Director   July 22, 2026

    /s/ Stephen L. Sabba

    Stephen L. Sabba, M.D.

       Director   July 22, 2026

    /s/ Martine Zimmermann

    Martine Zimmermann, Pharm.D.

       Director   July 22, 2026
    Get the next $LGND alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LGND

    DatePrice TargetRatingAnalyst
    7/21/2026$387.00Buy
    Citigroup
    3/11/2026$244.00Buy
    BofA Securities
    12/9/2025$270.00Buy
    Citigroup
    4/10/2025$143.00Buy
    Stifel
    10/3/2024$135.00Outperform
    Oppenheimer
    7/30/2024$130.00Outperform
    RBC Capital Mkts
    2/22/2022$180.00 → $130.00Buy
    Benchmark
    2/18/2022$185.00 → $165.00Overweight
    Barclays
    More analyst ratings

    $LGND
    SEC Filings

    View All

    SEC Form S-8 filed by Ligand Pharmaceuticals Incorporated

    S-8 - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

    7/22/26 4:52:54 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

    7/14/26 9:20:16 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

    6/25/26 5:00:27 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    XOMA Royalty Announces Closing of Its Acquisition by Ligand

    EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has completed its previously announced acquisition of XOMA Royalty. Pursuant to the terms of the transaction announced on April 27, 2026, Ligand acquired all of the outstanding shares of XOMA Royalty common stock. XOMA Royalty stockholders received $39.00 in cash per share of XOMA Royalty common stock owned. XOMA Royalty stockholders and equity award holders also received one non-transferable Contingent Value Right ("CVR") per share entitling the holder to receive a portion of 75% of the net proceeds that may result from certain pending liti

    7/14/26 9:00:00 AM ET
    $XOMA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

    Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth Ligand to provide updated 5-year outlook during Investor Day on December 8, 2026 JUPITER, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced it has completed its acquisition of XOMA Royalty Corporation ("XOMA Royalty"), a biotechnology royalty aggregator, for $39.00 per share of common stock in cash, for a total equity value of approximately $739 million. XOMA Royalty stockholders also received one

    7/14/26 9:00:00 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand Announces Closing of Convertible Senior Notes Offering

    Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand’s common stock upon conversion of the notes JUPITER, Fla., June 25, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") announced today that it completed its previously announced offering (the "offering") of 0.00% convertible senior notes due 2031 (the "notes"). The aggregate principal amount of the notes sold in the offering was $700.0 million, which includes the purchase of an additional $75.0 million aggregate principal amount

    6/25/26 4:01:00 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup resumed coverage on Ligand Pharma with a new price target

    Citigroup resumed coverage of Ligand Pharma with a rating of Buy and set a new price target of $387.00

    7/21/26 8:09:22 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Ligand Pharma with a new price target

    BofA Securities initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $244.00

    3/11/26 8:38:58 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Ligand Pharma with a new price target

    Citigroup initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $270.00

    12/9/25 8:50:31 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CLO & Secretary Reardon Andrew acquired $21,214 worth of shares (132 units at $160.71) as part of a pre-agreed trading plan, exercised 5,000 shares at a strike of $52.27 and sold $1,566,377 worth of shares (5,000 units at $313.28) as part of a pre-agreed trading plan, increasing direct ownership by 0.32% to 41,514 units (SEC Form 4)

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    7/6/26 5:11:31 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Espinoza Octavio acquired $2,732 worth of shares (17 units at $160.71), increasing direct ownership by 0.06% to 27,696 units (SEC Form 4)

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    7/6/26 5:11:09 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Davis Todd C acquired $21,214 worth of shares (132 units at $160.71), increasing direct ownership by 0.07% to 199,513 units (SEC Form 4)

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    7/6/26 5:10:32 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGND
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Davis Todd C bought $1,000,456 worth of shares (9,510 units at $105.20), increasing direct ownership by 6% to 161,234 units (SEC Form 4)

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    5/13/25 8:05:16 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Espinoza Octavio bought $156,090 worth of shares (1,500 units at $104.06), increasing direct ownership by 6% to 27,932 units (SEC Form 4)

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    5/13/25 8:04:05 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Davis Todd C bought $243,480 worth of shares (2,500 units at $97.39), increasing direct ownership by 2% to 123,010 units (SEC Form 4)

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    8/9/24 5:52:17 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGND
    Financials

    Live finance-specific insights

    View All

    Ligand Reports First Quarter 2026 Financial Results

    First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. "The first few months of 2026 have al

    5/7/26 7:00:00 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

    Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 20272 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla. and EMERYVILLE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporate

    4/27/26 7:00:00 AM ET
    $LGND
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand to Report First Quarter 2026 Financial Results on May 7, 2026

    JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update. Conference Call and Webcast Information   Date:  Thursday, May 7, 2026   Time: 8:30 a.m. Eastern time   Conference Call: United States (Local): +1 (585) 542-9983 United States (Toll-Free): +1 (833) 461-5787 International: Global Dial-in NumbersMeeting ID: 304603090   Webcast: Live and replay webcasts of the call are available here.    About LigandLigand is a

    4/22/26 7:00:00 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGND
    Leadership Updates

    Live Leadership Updates

    View All

    Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

    The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me

    7/2/25 7:00:00 AM ET
    $CHRO
    $LGND
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

    WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p

    10/17/24 7:30:00 AM ET
    $LFCR
    $LGND
    $PIRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OmniAb Announces Completion of Spin-Off and Business Combination

    Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "

    11/1/22 4:01:00 PM ET
    $AHPA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated

    SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

    11/1/24 4:07:52 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ligand Pharmaceuticals Incorporated

    SC 13G - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

    2/14/24 6:26:25 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated (Amendment)

    SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

    2/13/24 5:08:05 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care